Business
Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.